Druglike molecules produced by gut bacteria can affect gut, immune health Stanford researchers found that manipulating the gut microbe Clostridium sporogenes changed levels of molecules in the bloodstreams of mice and, in turn, affected their health.

Clinical trial points to new cell therapy for relapsed leukemia patients Instead of targeting a molecule called CD19 on the surface of the cancer cells, the new therapy targets a molecule called CD22.

Stem cells that generate fat tissue have circadian clock New discoveries about the circadian-clock machinery in the precursors to fat cells may explain why shift workers are prone to metabolic diseases, such as diabetes, a Stanford study finds.

Drug for spinal muscular atrophy prompts ethical dilemmas Medical experts at Stanford and their colleagues at several other universities have raised ethical questions about the way a treatment for spinal muscular atrophy is being used.

Second ‘don’t eat me’ signal found on cancer cells CD47 is an important inhibitor of cancer-killing immune cells called macrophages. Now Stanford researchers have identified another, similar way to activate macrophages to destroy cancer cells.

Study links common male medical condition to vascular disease Harnessing the power of big data, Stanford researchers found that enlarged veins on the scrotum are linked with a higher risk of vascular and metabolic disease in men.